Precision Oncology Expands Oral Options for Breast Cancer

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawRapid advances in precision medicine are redefining treatment for hormone receptor (HR)-positive, HER2-negative breast cancer, with a growing arsenal of oral targeted therapies guided by tumor genomics.At the NASP 2025 Annual Meeting & Expo, in Denver, Walgreens oncology specialists Laly Havern, PharmD, BCACP, and Khadijah Khan, CPhT, described how agents acting on the estrogen receptor and the PI3K/AKT (p